This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Cancer and Metabolism
joint with Advances in Hypoxic Signaling: From Bench to Bedside
Organizer(s): Reuben J. Shaw and David M. Sabatini
Date: February 12 - 17, 2012
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Astellas Pharma Inc., Celgene Corporation, Pfizer Inc. and Takeda Pharmaceutical Company Limited
Summary of Meeting:
Although altered glucose metabolism was first noted as a characteristic of tumor cells by Otto Warburg in the 1920s, the molecular underpinning for this observation did not begin to be appreciated fully until the past decade. This area has exploded over the last five years with the identification of extensive interactions of genuine tumor suppressor genes and oncogenes with metabolic control. The increased biosynthetic needs of tumor cells demand a reprogramming of cellular metabolism, which also creates increased energy demands and makes tumor cells more vulnerable to interventions targeting their metabolism. The goal of the Keystone Symposia meeting on Cancer and Metabolism is to bring together leaders in the fields of cancer and metabolic control with those studying the signaling pathways linking and governing each. The latest discoveries will be discussed as well as how this knowledge can be exploited to design future cancer therapeutics. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in Hypoxic Signaling: From Bench to Bedside, which will share a keynote address and a plenary session with this meeting.
Scholarship Deadline: October 13 2011
Discounted Abstract Deadline: October 13 2011
Abstract Deadline: November 14 2011
Discounted Registration Deadline: December 12 2011
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Astellas Pharma Inc.Celgene CorporationPfizer Inc.Takeda Pharmaceutical Company Limited
We gratefully acknowledge additional support for this conference from:
Cell Signaling Technology, Inc.Coy Laboratory Products Inc.Educational grant from Millennium Pharmaceuticals, Inc., The Takeda Oncology CompanyMyriad-RBMNovartis Institutes for BioMedical ResearchNovus Biologicals, Inc.Seahorse Bioscience, Inc.Zymo Research Corporation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

EMBO Young Investigator Programme
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
EMBO (European Molecular Biology Organization)
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA162886-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found